Small Cell Lung Cancer

  • R. Scott Bermudez
  • Brian Missett
  • Daphne A. Haas-Kogan


SCLC accounts for 15–20% of lung cancer cases with decreasing incidence. Approximately 1/3 of patients present with limited stage disease and the remainder present with extensive stage disease. More than 95% of cases are associated with a history of tobacco exposure. Ten to 15% of patients present with brain metastases and 2 year incidence after chemo-RT is 50–80%. SCLC is the most common solid tumor associated with paraneoplastic syndromes: SIADH, ACTH production syndrome, and Eaton–Lambert syndrome. Histopathologic hallmarks include dense sheets of small, round to fusiform cells with scant cytoplasm, extensive necrosis, and a high mitotic rate. Pathologic subtypes (pure or classic, variant, and mixed) carry the same prognosis. Most important prognostic factors are stage and performance status.


Brain Metastasis Lung Cancer Case Prophylactic Cranial Irradiation High Mitotic Rate Common Solid Tumor 


  1. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341:476-484.Google Scholar
  2. Chang JY, Bradley JD, Govindan R, Komaki R. Lung. In: Halperin EC, Perez CA, Brady LW, et al., editors. Principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. pp. 1076-1108.Google Scholar
  3. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al. Systematic Review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006;17:543-552.PubMedCrossRefGoogle Scholar
  4. De Ruysscher D, Pijls-Johannesma M, Bentzen S, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small cell lung cancer. J Clin Oncol 2006;24:1057-1063.PubMedCrossRefGoogle Scholar
  5. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004;22:4837-4845.PubMedCrossRefGoogle Scholar
  6. Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 2004;9:665-672.PubMedCrossRefGoogle Scholar
  7. Jeremic B, Shibamoto Y, Nikolic N. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999;17:2092-2099.PubMedGoogle Scholar
  8. Komaki R, Travis EL, Cox JD. The Lung and Thymus. In: Cox JD, Ang KK, editors. Radiation oncology: rationale, technique, results. 8th ed. St. Louis: Mosby; 2003. pp. 399-427.Google Scholar
  9. Komaki R, Paulus R, Ettinger DS, Videtic GM, Bradley JD, Glisson BS, Choy H. A phase II study of accelerated high-dose thoracic radiation therapy (AHTRT) with concurrent chemotherapy for limited small cell lung cancer: RTOG 0239. J Clin Oncol 2009;27:7s (suppl; abstr 7527).Google Scholar
  10. Le Pechoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 2203-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009;10:467-474.PubMedCrossRefGoogle Scholar
  11. Miller KL, Marks LB, Sibley GS, et al. Routine use of approximately 60 Gy once daily thoracic irradiation for patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;56:355-359.PubMedCrossRefGoogle Scholar
  12. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Available at: Accessed on May 19, 2009.
  13. Pignon JP, Arriagada A, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;3:1618-1624.CrossRefGoogle Scholar
  14. Roof KS, Fidias P, Lynch TJ, et al. Radiation dose escalation in limited-stage small cell lung cancer. Int J Radiat Oncol Biol Phys 2003;57:701-708.PubMedCrossRefGoogle Scholar
  15. Rosenzweig KE, Krug LM. Tumors of the Lung, Pleura, and Mediastinum. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology. 2nd ed. Philadelphia: Saunders; 2004. pp. 779-810.Google Scholar
  16. Schild SE, Bonner JA, Shanahan TG, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:943-951.PubMedCrossRefGoogle Scholar
  17. Schild SE, Curran WJ. Small Cell Lung Cancer. In: Gunderson LL, Tepper JE, et al., editors. Clinical radiation oncology, 2nd ed. Philadelphia: Churcill Linigstone; 2007. pp. 897-909.Google Scholar
  18. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664-672.PubMedCrossRefGoogle Scholar
  19. Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-271.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York 2010

Authors and Affiliations

  • R. Scott Bermudez
    • 1
  • Brian Missett
    • 2
  • Daphne A. Haas-Kogan
    • 1
  1. 1.Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Radiation OncologyKaiser Permanente Santa ClaraSanta ClaraUSA

Personalised recommendations